SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.01-1.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug who wrote (168)2/15/1998 8:49:00 AM
From: Omer Shvili  Read Replies (4) of 340
 
In your post you refer to your projections, meaning you claim to know Teva's business. However, if that was the case the least you would have known is their MS drug is called Copaxone and not Copazone, like you call it.
The window for Copaxone isn't closing, and there were other drugs on the market when Copaxone got FDA approval (Biogen's product is dominant). There are other MS drugs expected to reach the market but didn't get approval yet. Teva's numbers - 6,000 users of Copaxone - met Marion's target, and only fell short of analysts expectations. I'm sure Teva will make money on Copaxone in '98 (maybe not as much as analysts expected, but it will contribute to bottom line), and their generic business is doing great even with the tougher competition (Teva is one of the leaders in this market, with a rich pipeline). Your numbers ( $1.30 - $1.80 ) are way off, wait 12 months and you'll understand how off they are.

Omer
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News